结合基因突变谱与体外药物敏感性预测急性髓系白血病结局
本研究在按西班牙PETHEMA指南统一治疗的成人AML队列中,联合下一代测序(NGS,n=190)和体外PharmaFlow药物敏感性检测(n=74)预测标准诱导治疗反应及结局。基于NGS和体外药敏的新评分可改善现有预后分层并指导个体化治疗以减少耐药。
要点
- 联合NGS与体外药敏的新评分可改善AML预后分层
核心结论
- 结合NGS突变谱与体外PharmaFlow药敏的新评分可改善AML预后风险分层并指导个体化治疗以减少耐药。
研究设计与样本
- 在按西班牙PETHEMA指南统一治疗的成人AML队列中,行NGS突变谱分析(n=190)和体外PharmaFlow检测(n=74)覆盖10种最常用AML诱导治疗药物。
主要发现
- 体外PharmaFlow结果与临床诱导反应高度相关(69%)。
临床怎么用
- 对AML患者可联合NGS突变谱与体外药物敏感性检测进行预后分层,识别高危患者并指导个体化治疗以减少耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Refractoriness to induction therapy and relapse after complete remission are the leading causes of death in patients with acute myeloid leukaemia (AML). This study focussed on the prediction of response to standard induction therapy and outcome of patients with AML using a combined strategy of mutational profiling by next-generation sequencing (NGS, n = 190) and ex vivo PharmaFlow testing (n = 74) for the 10 most widely used drugs for AML induction therapy, in a cohort of adult patients uniformly treated according to Spanish PETHEMA guidelines. We identified an adverse mutational profile (EZH2, KMT2A, U2AF1 and/or TP53 mutations) that carries a greater risk of death [hazard ratio (HR): 3·29, P < 0·0001]. A high correlation was found between the ex vivo PharmaFlow results and clinical induction response (69%). Clinical correlation analysis showed that the pattern of multiresistance revealed by ex vivo PharmaFlow identified patients with a high risk of death (HR: 2·58). Patients with mutation status also ran a high risk (HR 4·19), and the risk was increased further in patients with both adverse profiles (HR 4·82). We have developed a new score based on NGS and ex vivo drug testing for AML patients that improves upon current prognostic risk stratification and allows clinicians to tailor treatments to minimise drug resistance.
引用
- Onecha E, Ruiz-Heredia Y, Martínez-Cuadrón D, et al. Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity. Br J Haematol. 2020. PMID: 32068246. doi:10.1111/bjh.16432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。